Filtered By:
Specialty: Drugs & Pharmacology
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 215 results found since Jan 2013.
Cardiovascular Event Rates After Myocardial Infarction or Ischaemic Stroke in Patients with Additional Risk Factors: A Retrospective Population-Based Cohort Study
ConclusionDespite previous use of moderate- or high-intensity statins, patients with a history of MI or IS, and additional risk factors remain at very high cardiovascular risk.
Source: Advances in Therapy - July 26, 2021 Category: Drugs & Pharmacology Source Type: research
Effect of More Intensive LDL-C-Lowering Therapy on Long-term Cardiovascular Outcomes in Early-Phase Acute Coronary Syndrome: A Systematic Review and Meta-analysis
Clin Ther. 2021 Jun 3:S0149-2918(21)00215-0. doi: 10.1016/j.clinthera.2021.04.019. Online ahead of print.ABSTRACTPURPOSE: The effect of more intensive LDL-C-lowering therapy (ILLT) on long-term cardiovascular outcomes during the early phase of acute coronary syndromes (ACSs) remains uncertain. We aimed to explore the influence of more intensive LDL-C-lowering therapyduring the early disease phase on long-term cardiovascular events among patients with ACSs.METHODS: Randomized controlled trials that focused on the effect of more ILLT during early-phase ACSs on long-term major adverse cardiac events (MACEs) were searched in e...
Source: Clinical Therapeutics - June 7, 2021 Category: Drugs & Pharmacology Authors: Siyao Jin Xiaolu Nie Yuxi Li Jinjie Yuan Yimin Cui Libo Zhao Source Type: research
Disease Status –Dependent Drug–Herb Interactions: NASH Lowered the Risk of Hepatotoxicity in Rats Coadministered With Simvastatin and Gardenia jasminoides J. Ellis
Concurrent use of simvastatin (SV) and Gardenia jasminoides J. Ellis (GJ) was adopted in patients with multi-morbidity, such as stroke rehabilitation patients with NASH. Although hepatotoxicity has been reported in both of them and NASH could alter the pharmacokinetics of drugs/herbs, the interaction between SV and GJ and the related hepatotoxicity remained uninvestigated under neither healthy nor NASH condition. The current study aimed to evaluate the potential hepatotoxicity resulted from the interactions between SV and GJ in both healthy and NASH rats. Both healthy and NASH rats received two-week SV (p. o., 8.66 mg/kg,...
Source: Frontiers in Pharmacology - April 23, 2021 Category: Drugs & Pharmacology Source Type: research
A Combination of Atorvastatin and Aspirin Enhances the Pro-Regenerative Interactions of Marrow Stromal Cells and Stroke-Derived Monocytes In Vitro
Conclusion: Atorvastatin, alone and in combination with aspirin can promote anti-inflammatory effect by modulating the secretome profile of Mo and MSCs. Our results suggest that stroke trials involving the use of intravenous MSCs should consider the effect of aspirin and atorvastatin, both of which are administered to the majority of hospitalized ischemic stroke patients.
Source: Frontiers in Pharmacology - April 20, 2021 Category: Drugs & Pharmacology Source Type: research
Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting
Conclusion: Alirocumab is not cost-effective in general MI population based on current discounted price. High long-term costs of alirocumab may be offset by health benefit in patients with polyvascular disease (3 beds).
Source: Frontiers in Pharmacology - April 14, 2021 Category: Drugs & Pharmacology Source Type: research
Bempedoic acid: a cholesterol lowering agent with a novel mechanism of action
Expert Rev Clin Pharmacol. 2021 Mar 11. doi: 10.1080/17512433.2021.1901579. Online ahead of print.ABSTRACTINTRODUCTION: Dyslipidemia is a common condition that increases the risk of heart diseases and stroke. High levels of low-density lipoprotein-cholesterol (LDL-C) is correlated with a higher risk for heart disease. A drug class known as "statins" is the gold standard for LDL-C-lowering, but its use in some patients is limited by its adverse effects of myalgias and myopathies. Use of other LDL-C-lowering agents are frequently limited by cost and degree of efficacy. Additionally, many high-risk atherosclerotic cardiovascu...
Source: Expert Review of Clinical Pharmacology - March 11, 2021 Category: Drugs & Pharmacology Authors: Huyen Nguyen Ikenna Akamnonu Tianrui Yang Source Type: research
Safety and Efficacy of Perioperative Use of Evolocumab in Myocardial Infarction Patients: Study Protocol for a Multicentre Randomized Controlled Trial
This study aims to evaluate the safety and efficacy of this treatment regimen.MethodsA multicentre, prospective, randomized, controlled superiority trial will be conducted in 530 statin-na ïve MI patients. All eligible patients will be randomized to the evolocumab group (140 mg subcutaneously injected once before revascularization + 14 days after the first dose) or the control group (no evolocumab injection). Evolocumab will then be administered depending on the patient's lipid profile. Both groups will be treated simultaneously with standardized secondary preventive medications. The primary end points are major adv...
Source: Advances in Therapy - February 27, 2021 Category: Drugs & Pharmacology Source Type: research
Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway.
In this study, Sprague-Dawley rats were fed a high fat diet (HFD) for 5 weeks to establish a hyperlipidaemia model; then, the rats were orally administered KLX (20, 40, and 80 mg kg-1·d-1) or atorvastatin calcium (AT, 10 mg kg-1·d-1) once a day for 2 weeks. KLX had prominent effects on reducing blood lipids, hepatic lipid accumulation, body weight and the ratio of liver weight/body weight. Furthermore, KLXdramatically reduced the total cholesterol (TC) and triglyceride (TG) levels and lipid accumulation in a HepG2 cell model of dyslipidaemia induced by 1 mmol/L oleic acid (OA). KLX may decrease lipid levels by phosphoryl...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 14, 2020 Category: Drugs & Pharmacology Authors: Li X, Hu X, Pan T, Dong L, Ding L, Wang Z, Song R, Wang X, Wang N, Zhang Y, Wang J, Yang B Tags: Biomed Pharmacother Source Type: research
Effect of atorvastatin on expression of TLR4 and NF- κB in stroke rats and its protective effect on brain.
CONCLUSIONS: Atorvastatin can effectively reduce the expression of TLR4 and NF-κB in brain tissue of stroke rats, and has a certain protective effect on cerebral nerve function, which is expected to be the first choice for stroke treatment in the future.
PMID: 33155240 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - November 10, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis.
CONCLUSIONS: Among statin-treated patients with CV risk, the use of PCSK9i was associated with improving CV outcomes. The use of PCSK9i was well tolerated, but had significantly injection-site reactions.
PMID: 33137282 [PubMed - as supplied by publisher]
Source: Journal of Pharmacy and Pharmaceutical Sciences - November 3, 2020 Category: Drugs & Pharmacology Tags: J Pharm Pharm Sci Source Type: research
Mechanism Study of the Protective Effects of Sodium Tanshinone IIA Sulfonate Against Atorvastatin-Induced Cerebral Hemorrhage in Zebrafish: Transcriptome Analysis
This study also provided evidence of biomarkers involved in hemorrhage stroke and improved understanding of the effects of HMG-COA reductase inhibition on vascular permeability and cerebral hemorrhage.
Source: Frontiers in Pharmacology - October 1, 2020 Category: Drugs & Pharmacology Source Type: research
Statin use and safety concerns: an overview of the past, present and the future.
Authors: Mulchandani R, Lyngdoh T, Kakkar AK
Abstract
INTRODUCTION: Dyslipidemia is a significant risk factor for cardiovascular disorders and contributes to significant morbidity and mortality associated with CAD and stroke worldwide. Statins are the most commonly prescribed drugs for prevention and management of dyslipidemia globally. Although they provide immense therapeutic benefit, they are associated with clinically significant adverse effects, predominantly muscle, nerve, liver and cognition-related besides new onset diabetes. This has sparked various controversies, bringing to the fore, ambiguities that con...
Source: Expert Opinion on Drug Safety - July 18, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Association Between an Acute, Drug-Induced Decrease in High-Density Lipoprotein Cholesterol Levels and Risk of Cardiovascular Events
ConclusionPatients with a short-term, drug-induced decrease in HDL-C had a moderately increased long-term risk of CV events compared with those with constant HDL-C levels.Trial Registration Number207595 (GlaxoSmithKline Trial registry;https://www.gsk-studyregister.com/).
Source: Clinical Drug Investigation - June 17, 2020 Category: Drugs & Pharmacology Source Type: research
